

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert F. Hofmann, et al.

Serial No.: 09/822,773

Filed: March 30, 2001


Art Unit: 1614

Examiner: John D. Pak

For: **USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN
ARTERIOSCLEROSIS**

Commissioner for Patents
Box: NON-FEE AMENDMENT
Washington, D. C. 20231

Sir:



RESPONSE TO RESTRICTION REQUIREMENT


Applicants wish to thank the Examiner for his advice regarding the current election of species, which was given on November 7, 2002 by telephone.

In response to the Examiner's communication mailed October 21, 2002, Applicants hereby elect, without traverse, to prosecute in this application the following disclosed species:


- (i) reaction product from oxidation of alkene, wherein the alkene is geranylgeraniol;
- (ii) penetrating solvent such as DMSO;
- (iii) dye containing chelated divalent or trivalent metal such as porphyrin; and
- (iv) aromatic redox compound such as benzoquinone.

Applicants submit that the election of species (i) is now complete and respectfully request that the application be taken up for further examination.

Respectfully submitted,



T. Ling Chwang
Reg. No. 33,590
Jackson Walker L.L.P.
2435 North Central Expressway, Suite 600
Richardson, Texas 75080
Tel: (972) 744-2919
Fax: (972) 744-2909



Date